Pricing Log in Create free account
Saturday 17 October 2026 Export ATEC’s income statement to Excel — free account

Alphatec Holdings, Inc.

ATEC Healthcare Medical Devices

Alphatec Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $764.2 million, up 25.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.1%, EPS grew 40.7%, free cash flow fell 146.9% and total debt fell 7.79%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

10.45 0.48 −4.39%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−16.4×
Dividend yield
—
F-score
6/9
Altman Z
0.89
Beneish M
−3.43
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.01
Total sells 92.64
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — 1 — — — 1 —
Sell 12 13 1 2 5 — — 1 — 1 — —
Insider Ownership 22.86%

Capital & Financial Ratios $m

Market Cap 1,690.00
Revenue 815.05
Net Income (109.99)
Free Cash Flow (5.74)
Net Debt 392.08
Current Ratio 1.89 (at or above 1.5: strong)
Debt/Equity (42.32) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (16.40) (negative: loss-making)
P/S ratio 2.01
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 553.31% (at or above 15%: strong)
Next Y EPS Growth 86.61% (at or above 15%: strong)
Next Y revenue growth 15.43% (at or above 10%: strong)
Next 5Y EPS Growth 160.23% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.6×, against a ten-year median of 3.0×; over the ten years it ranged from 0.3× in 2017 to 7.9× in 2021.
P/S against its own 10 years 39.18%
10-year low 10-year high
EV/Sales against its own 10 years 41.39%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 221 139 161 119
Receivables 73 83 97 110
Inventory 137 175 169 195
Other — — — —
451 417 451 449
2023 2024 2025 Q'26
Payables 49 53 41 62
ST’ Debt 2 2 — —
Other 14 10 10 11
158 153 219 238

Compound Annual Growth %

10y 5y 3y
Sales 18.98% 39.46% 29.62%
Cash Flow 16.15% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (37.46%) 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 192 214 — — —
’25 169 186 197 213 764
’24 138 146 151 177 612
’23 109 117 118 138 482
’22 71 84 90 106 351
’21 44 62 63 74 243
’20 30 30 41 44 145
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 1 21 — — —
’25 (5) 16 14 21 45
’24 (38) (11) (5) 11 (45)
’23 (18) (18) (17) (25) (78)
’22 (25) (27) (15) (8) (75)
’21 (19) (17) (23) (15) (73)
’20 (17) (13) (10) (7) (46)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (2) — — —
’25 (17) 3 3 6 (4)
’24 (72) (47) (25) 7 (138)
’23 (35) (38) (39) (53) (165)
’22 (38) (42) (30) (23) (133)
’21 (34) (37) (36) (34) (142)
’20 (20) (17) (15) (18) (70)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.22) (0.16) — — —
’25 (0.35) (0.27) (0.19) (0.14) (0.96)
’24 (0.34) (0.29) (0.28) (0.23) (1.13)
’23 (0.40) (0.43) (0.35) (0.37) (1.54)
’22 (0.43) (0.36) (0.35) (0.33) (1.47)
’21 (0.26) (0.39) (0.43) (0.40) (1.50)
’20 (0.33) (0.25) (0.24) (0.35) (1.18)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 1.80 1.58 2.02 1.18 2.19 10.31 5.73 8.66 4.88 8.81

Analyst estimates 2026–2028

Powerpack
High 9.65 5.80 4.21 7.75 14.97 19.36 13.65 19.14 17.34 22.66
People
People Employees 162 138 195 227 296 561 705 839 867 913
Revenue/emp, $m 0.74 0.74 0.47 0.50 0.49 0.43 0.50 0.57 0.71 0.84
Income, $m
Income, $m Revenue 120 102 92 113 145 243 351 482 612 764
Gross margin, % 63.31 67.06 68.97 68.41 70.76 64.87 66.42 61.36 66.72 67.63
EBT (31) (5) (30) (57) (79) (144) (152) (187) (162) (143)
EBT margin, % (25.73) (4.50) (32.90) (50.38) (54.43) (59.27) (43.32) (38.76) (26.50) (18.77)
Net income (30) (2) (29) (57) (79) (143) (151) (187) (162) (143)
Depreciation 15 7 7 9 12 32 46 63 88 105
Per share, $
Per share, $ Revenue 14.01 7.96 2.60 2.17 2.16 2.53 3.39 3.98 4.28 5.09
Earnings (3.57) (0.18) (1.20) (1.09) (1.18) (1.50) (1.47) (1.54) (1.13) (0.96)
Cash flow (1.16) (0.68) (0.73) (0.63) (0.69) (0.76) (0.73) (0.65) (0.31) 0.30
Capex (0.91) (0.51) (0.17) (0.25) (0.36) (0.71) (0.56) (0.72) (0.65) (0.33)
Free cash flow (2.07) (1.19) (0.90) (0.88) (1.05) (1.47) (1.29) (1.36) (0.96) (0.03)
Book value (4.84) (2.08) 0.50 0.84 1.94 0.83 (0.34) 0.64 (0.10) 0.08
Shares, m 9 13 35 52 67 96 103 121 143 150
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.23 0.34 0.88 3.27 6.72 4.52 3.49 3.73 2.15 4.13
P/B 0.00 0.00 4.60 8.50 7.49 13.84 0.00 23.05 0.00 254.09
EV/Sales 0.45 0.52 1.06 3.33 6.27 5.11 4.30 4.34 2.86 4.66
EV/FCF (2.97) (3.30) (2.99) (8.05) (12.84) (8.70) (11.30) (12.65) (12.70) (807.85)
Cash, $m
Cash, $m Operating cash flow (10) (9) (26) (33) (46) (73) (75) (78) (45) 45
Capex (8) (6) (6) (13) (24) (69) (58) (87) (93) (50)
Free cash flow (18) (15) (32) (46) (70) (142) (133) (165) (138) (4)
Balance, $m
Balance, $m Working capital 33 37 45 72 126 230 117 294 264 232
Total debt 46 41 46 54 43 331 369 513 576 501
Net debt 27 19 17 7 (65) 144 285 292 437 341
Shareholders’ equity (42) (27) 18 44 130 79 (35) 78 (14) 12
Returns, %
Returns, % ROA (24.88) (2.57) (39.66) (38.07) (36.64) (34.33) (27.68) (28.15) (20.51) (18.30)
ROIC 0.00 0.00 (41.14) (58.56) (56.43) (35.86) (36.75) (29.29) (20.11) (14.54)
ROE 76.65 6.73 934.91 (186.27) (91.05) (136.68) (676.09) (859.11) (507.05) 16,450.51
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Alphatec Holdings, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
UFPT UFP Technologies, Inc. $2.3B 31.2× 23.6× +15.07% (above 0%: growing) +20.63% (above 0%: growing) −35.77% (below 0%: shrinking) 29.27% 16.15% Compare
BFLY Butterfly Network, Inc. $2.1B — (loss-making) — (loss-making) +39.47% (above 0%: growing) n/m −113.85% (below 0%: shrinking) 71.41% (41.90%) Compare
AXGN AxoGen, Inc. $2.1B — (loss-making) — (loss-making) +23.06% (above 0%: growing) n/m −17.36% (below 0%: shrinking) 72.67% (3.09%) Compare
INSP Inspire Medical Systems, Inc. $2.0B 14.8× 93.5× −7.60% (below 0%: shrinking) n/m +322.84% (above 0%: growing) 85.48% (0.26%) Compare
ESTA Establishment Labs Holdings Inc. $1.8B — (loss-making) — (loss-making) +31.66% (above 0%: growing) n/m +2.75% (above 0%: growing) 70.64% (6.35%) Compare
ATEC Alphatec Holdings, Inc. $1.7B — (loss-making) — (loss-making) +15.07% (above 0%: growing) n/m −146.87% (below 0%: shrinking) 72.17% (0.89%)
NVCR NovoCure Limited $1.7B — (loss-making) — (loss-making) +15.60% (above 0%: growing) n/m +105.68% (above 0%: growing) 77.61% (5.75%) Compare
CNMD CONMED Corporation $1.4B 25.3× 8.8× +0.33% (above 0%: growing) +11.59% (above 0%: growing) +45.96% (above 0%: growing) 57.49% 10.60% Compare
BVS Bioventus Inc. $1.2B 16.4× 21.4× +3.76% (above 0%: growing) +345.45% (above 0%: growing) −25.11% (below 0%: shrinking) 68.97% 12.48% Compare
Median of peers $1.9B 20.8× 22.5× +15.34% +20.63% −7.30% 71.03% (1.67%)

All 149 Medical Devices stocks →

Alphatec Holdings, Inc. (ATEC) key facts

  • Strength: Alphatec Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $764.2 million, up 25.0% from fiscal 2024.
  • Alphatec Holdings, Inc. (ATEC) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ATEC traded at $10.45, a market capitalization of $1.7 billion.
  • Return on equity was 16,450.5% and debt-to-equity -42.32.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.89 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Alphatec Holdings, Inc. (ATEC) Latest News

24 Jul

Impact 5 ·
stockrow.com/ATEC · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com